Immunovia AB was founded in 2007 by researchers from the Department of Immunotechnology at Lund University and CREATE Health (the Center for Translational Cancer Research) in Lund, Sweden.
Our strategy is to decipher the wealth of information available in blood – and translate it into clinically useful tools to diagnose complex diseases such as cancer and autoimmune disorders, earlier and more accurately than previously possible.
Immunovia’s unique technology platform – IMMrayTM – is an antibody-based multiplex test that is designed to provide a snapshot of the immune system response – based on the information available in a single drop of blood.
But IMMrayTM is more than a technology, it is a systematic approach, based on cutting-edge bioinformatics, to finding the most clinically relevant changes that appear in the blood, and combining this knowledge into a “disease fingerprint” – also called a biomarker signature – that is highly specific to the particular disease.
Our first diagnostic test, IMMrayTM PanCan-d, is a unique blood test for the early detection of pancreatic cancer that has the potential to dramatically increase patient survival rates: from 5–8% to up to 49%. Retrospective studies show that the test is able to detect stage I and stage II pancreatic cancer with an accuracy of 96%. A test with such a high level of accuracy would give clinicians a much greater chance of finding the cancer when it is still resectable by surgical procedures. The company is currently performing clinical validation studies for the commercialization of IMMray™ PanCan-d.
In collaboration with Create HEALTH translation cancer center at Lund University and others, we also have on-going projects in discovery phase targeting other cancers as well as autoimmune diseases. An autoimmune development program has been initiated at Immunovia based on very good results from a differential diagnosis study of SLE versus RA, Sjögrens syndrome and Vasculatis. Immunovia is currently performing further complementary and validation retrospective studies to define the product development strategy within autoimmunity.
Immunovia has been a listed company since 2015, with shares traded (as IMMNOV) on Nasdaq First North in Stockholm and since 3 April 2018 traded on Nasdaq Stockholm. The company has 40+ employees, is headquartered in Lund, Sweden and has reference laboratories in both Lund, Sweden and Boston, USA.
- Pancreatic registry in Japan – 20 years of experience, 2004.
- Ingvarsson J et al.Proteomics 2008 8(11):2211-9.
- Wingren et al. Cancer Res. 2012 15;72(10):2481-90.
- Gerdtsson et al. Int Journal of Proteomics 2015;2015:587250.
- Gerdtsson et al. J Mol Oncol, 2016. 10, 1305-1316.
- Mellby et al. Serum biomarker signature-based liquid biopsy for diagnosis of early-stage pancreatic cancer. J Clin Oncol. 2018 Aug 14. doi: 10.1200/JCO.2017.77.6658. [Epub ahead of print]